Amneal Pharmaceuticals

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Amneal Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 2 currently recruiting 6 completed later-stage tilt upper quartile by trial count

Amneal Pharmaceuticals: 8 sponsored US clinical trials, 2 recruiting.

Amneal Pharmaceuticals sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 6 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ocular Hypertension, with 2 trials.

Upper-quartile sponsor footprint

Amneal Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

NCT06267274
RECRUITING Phase 3

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

NCT05401357
COMPLETED Phase 1

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females

NCT06467201
COMPLETED Phase 3

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

NCT02110368
COMPLETED Phase 3

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT02125253
COMPLETED Phase 3

Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo

NCT01779947
COMPLETED Phase 3

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

NCT01650051
COMPLETED Phase 3

Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo

NCT01064024

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 3 6

Therapeutic Areas

Ocular Hypertension 2
Primary Hypogonadism 1
Healthy Postmenopausal Women 1
Glaucoma Open-Angle 1
Open Angle Glaucoma 1
Hypogonadotropic Hypogonadism 1

Where Amneal Pharmaceuticals enrollment is open (later-stage tilt)

2 recruiting of 8 indexed (25% open); 6 completed (75%).

Phase mix: 6 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Ocular Hypertension (2 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Amneal Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Amneal Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%10%20%30%40% Total trials Recruiting share Amneal PharmaceuticalsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Abdul Latif Jameel Poverty Action LabAccutar BiotechnologyAdrienne G. WaksAdvocate Hospital System
Amneal Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Amneal Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Amneal Pharmaceuticals page

8 registered trials is a research-attention snapshot, not an endorsement of Amneal Pharmaceuticals or any single study.

  • 2 of Amneal Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Ocular Hypertension is the condition Amneal Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ocular Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Amneal Pharmaceuticals pipeline card: 8 registered trials from official public datasets.Report a data error.